Prophylaxis and treatment of GVHD: EBMT–ELN working group recommendations for a standardized practice-Reference-Cited by-同舟云学术

Prophylaxis and treatment of GVHD: EBMT–ELN working group recommendations for a standardized practice

Published:2013-07-29 Issue:2 Volume:49 Page:168-173
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Ruutu T, ,Gratwohl A,de Witte T,Afanasyev B,Apperley J,Bacigalupo A,Dazzi F,Dreger P,Duarte R,Finke J,Garderet L,Greinix H,Holler E,Kröger N,Lawitschka A,Mohty M,Nagler A,Passweg J,Ringdén O,Socié G,Sierra J,Sureda A,Wiktor-Jedrzejczak W,Madrigal A,Niederwieser D

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/bmt2013107.pdf

Reference33 articles.

1. Patterson J, Prentice HG, Brenner MK, Gilmore M, Janossy G, Ivory K et al. Graft rejection following HLA matched T-lymphocyte depleted bone marrow transplantation. Br J Haematol 1986; 63: 221–230.

2. Goldman JM, Gale RP, Horowitz MM, Biggs JC, Champlin RE, Gluckman E et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med 1988; 108: 806–812.

3. Bacigalupo A, Van Lint MT, Occhini D, Guolandi F, Lamparelli T, Sogno G et al. Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia. Blood 1991; 77: 1423–1428.

4. Ruutu T, Niederwieser D, Gratwohl A, Apperley JF, on behalf of the Chronic Leukaemia Working Party of the EBMT. A survey of the prophylaxis and treatment of acute GVHD in Europe: a report of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1997; 19: 759–764.

5. Ruutu T, van Biezen A, Hertenstein B, Henseler A, Garderet L, Passweg J et al. Prophylaxis and treatment of graft versus host disease after haematopoietic stem cell transplantation: a survey of centre strategies by the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2012; 47: 1459–1464.

Cited by 246 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunological and homeostatic pathways of alpha -1 antitrypsin: a new therapeutic potential;Frontiers in Immunology;2024-08-19

2. Early Access for Medicines in ITALY: The Case of Ruxolitinib for Patients with Graft-Versus-Host Disease;Journal of Clinical Medicine;2024-07-22

3. Gradual treatment effect from mesenchymal stem cell on steroid-refractory aGVHD in patients receiving above 8 infusions and with gut involvement: a multicenter, randomized, double-blind, placebo-controlled phase 2 trial;2024-07-16

4. Ruxolitinib for the treatment of acute graft-versus-host disease: a retrospective analysis;Annals of Hematology;2024-06-25

5. Post‐transplant‐cyclophosphamide and short‐term Everolimus as graft‐versus‐host‐prophylaxis in patients with relapsed/refractory lymphoma and myeloma—Final results of the phase II OCTET‐EVER trial;European Journal of Haematology;2024-04-14